This is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...
Read MoreThe year in brief Juli – SeptemberFinancial summary of the third quarter Net sales amounted to SEK 0 million (0,05 million). R&D costs amounted to SEK 10,9 million (8,8 million). Operating profit for the third quarter amounted to SEK...
Read MoreSecond quarter in brief as well as the period 1 January to 30 June 2021 Net sales for the period (January to June) amounted to SEK 0 million (SEK 0 million), of which the second quarter contributed SEK 0 million...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces that the recruitment of patients for the exploratory phase IIa study with KAND567 has ended after just over 80 percent of the originally planned number of COVID-19 patients have...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) announces today that the application for permission to start a phase IIa study evaluating the safety and cardioprotective effect of KAND567 in heart attack patients has been submitted to the...
Read MoreFirst quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...
Read Moretwo thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) reports preclinical research results, which show that the company's Fractalkine blockers have the potential to disrupt cancer cells' resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer...
Read MoreFourth quarter in brief as well as the period 1 January – 31 December 2020 Net sales for the period (January to December) amounted to SEK 0,1 million (3,2 million), of which the fourth quarter contributed SEK 0 million...
Read MoreThis is a translation of a press release in Swedish published December 29, 2020
Read More